The work herein describes the research of two separate projects: the purification of A-Raf and the crystallization and X-ray diffraction of Thermotoga maritima mannitol dehydrogenase (TmMtDH). <p>A-Raf is a one of three Raf isoforms of serine/threonine kinases involved in the mitogen-activated protein kinase (MAPK) pathway, a cell proliferation pathway that has been associated with many cancers. In addition, only the A-Raf isoform can uniquely bind to the regulatory subunit of phosphatidylinositol-3-kinase (PI3K), which is part of the Akt/PI3K pathway and is another important signaling molecule deregulated in human cancers. Therefore, the main focus of this study was to purify and crystallize this protein in order to characterize what makes A-Raf structurally unique from the other two Raf isoforms. <p>Several portions of A-Raf were purified throughout this study, but most research concentrated on the conserved region 2 and 3 (CR2 and CR3) domains of A-Raf and the full-length protein. The CR2/CR3 domains and full-length A-Raf were purified by affinity chromatography on a glutathione Sepharose column and column fractions were analyzed by SDS-PAGE. Two different bands measuring approximately 75 kDa and 66 kDa resolved on the SDS-PAGE gel of full-length A-Raf while three bands measuring approximately 75 kDa, 66 kDa and 45 kDa resolved on the SDS-PAGE gel of the CR2/CR3 domains of A-Raf. The CR2/CR3 domains and full-length A-Raf were also extensively studied by mass spectrometry but results were inconclusive. Western blot analysis was also performed on the CR2/CR3 domains and full-length A-Raf. Results indicated that multiple bands were present and that degradation of the protein had taken place. A-Raf was thus deemed unsuitable for crystallization trials and the project was terminated.<p>Mannitol is an acyclic polyalcohol and is used commercially for several purposes including acting as an osmoregulatory compound in several pharmaceuticals and as an artificial sweetener in products targeted for diabetic patients. Commercially, mannitol is produced by the hydrogenation of 50% fructose/50% glucose syrup at high temperatures. However, the product of this process yields an excess of sorbitol and therefore the mannitol requires further purification. Mannitol dehydrogenase catalyzes the conversion of D-fructose to D-mannitol and has therefore been targeted for studies to produce a commercial mannitol bioreactor. The aims of this study included crystallization of the hyperthermophilic Thermotoga maritima (TmMtDH) mannitol dehydrogenase and subsequent X-ray diffraction and structure analysis. Dr. Claire Vieille at Michigan State University provided purified protein for crystallization trials. Two conditions produced diffraction quality crystals of TmMtDH. Condition 1 crystals grew in a solution containing 30% 2-methyl-2,4-pentanediol (MPD) plus 0.1 M HEPES-Na at pH 7.5. Condition 2 crystals grew in a solution containing 15-20% (w/v) polyethylene glycol (PEG) 4000 or 8000 plus 0.1 M sodium citrate at pH 4, 0.2 M sodium bromide and 10% glycerol. Crystals were flash cooled in liquid nitrogen and diffracted on the in-house diffractometer at the Saskatchewan Structural Sciences Center and at beamline 08ID-1 at the Canadian Light Source. Data were collected to 3.3 Å for the crystal that grew in condition 1 but the structure could not be solved before the completion of this project. The space group of the condition 1 crystal was P212121 with unit cell dimensions a = 83.43 Å, b = 120.61 Å, c = 145.76 Å.

The work herein describes the research of two separate projects: the purification of A-Raf and the crystallization and X-ray diffraction of Thermotoga maritima mannitol dehydrogenase (TmMtDH). <p>A-Raf is a one of three Raf isoforms of serine/threonine kinases involved in the mitogen-activated protein kinase (MAPK) pathway, a cell proliferation pathway that has been associated with many cancers. In addition, only the A-Raf isoform can uniquely bind to the regulatory subunit of phosphatidylinositol-3-kinase (PI3K), which is part of the Akt/PI3K pathway and is another important signaling molecule deregulated in human cancers. Therefore, the main focus of this study was to purify and crystallize this protein in order to characterize what makes A-Raf structurally unique from the other two Raf isoforms. <p>Several portions of A-Raf were purified throughout this study, but most research concentrated on the conserved region 2 and 3 (CR2 and CR3) domains of A-Raf and the full-length protein. The CR2/CR3 domains and full-length A-Raf were purified by affinity chromatography on a glutathione Sepharose column and column fractions were analyzed by SDS-PAGE. Two different bands measuring approximately 75 kDa and 66 kDa resolved on the SDS-PAGE gel of full-length A-Raf while three bands measuring approximately 75 kDa, 66 kDa and 45 kDa resolved on the SDS-PAGE gel of the CR2/CR3 domains of A-Raf. The CR2/CR3 domains and full-length A-Raf were also extensively studied by mass spectrometry but results were inconclusive. Western blot analysis was also performed on the CR2/CR3 domains and full-length A-Raf. Results indicated that multiple bands were present and that degradation of the protein had taken place. A-Raf was thus deemed unsuitable for crystallization trials and the project was terminated.<p>Mannitol is an acyclic polyalcohol and is used commercially for several purposes including acting as an osmoregulatory compound in several pharmaceuticals and as an artificial sweetener in products targeted for diabetic patients. Commercially, mannitol is produced by the hydrogenation of 50% fructose/50% glucose syrup at high temperatures. However, the product of this process yields an excess of sorbitol and therefore the mannitol requires further purification. Mannitol dehydrogenase catalyzes the conversion of D-fructose to D-mannitol and has therefore been targeted for studies to produce a commercial mannitol bioreactor. The aims of this study included crystallization of the hyperthermophilic Thermotoga maritima (TmMtDH) mannitol dehydrogenase and subsequent X-ray diffraction and structure analysis. Dr. Claire Vieille at Michigan State University provided purified protein for crystallization trials. Two conditions produced diffraction quality crystals of TmMtDH. Condition 1 crystals grew in a solution containing 30% 2-methyl-2,4-pentanediol (MPD) plus 0.1 M HEPES-Na at pH 7.5. Condition 2 crystals grew in a solution containing 15-20% (w/v) polyethylene glycol (PEG) 4000 or 8000 plus 0.1 M sodium citrate at pH 4, 0.2 M sodium bromide and 10% glycerol. Crystals were flash cooled in liquid nitrogen and diffracted on the in-house diffractometer at the Saskatchewan Structural Sciences Center and at beamline 08ID-1 at the Canadian Light Source. Data were collected to 3.3 Å for the crystal that grew in condition 1 but the structure could not be solved before the completion of this project. The space group of the condition 1 crystal was P212121 with unit cell dimensions a = 83.43 Å, b = 120.61 Å, c = 145.76 Å.

Würzburg, Univ., Diss., 2009. / Zsfassung in dt. Sprache.

The tuberous sclerosis-2 (Tsc-2) gene product, tuberin, functions as a renal tumor suppressor. Treatment of Eker (Tsc-2 EK/+) rats and primary renal epithelial cells derived from Tsc-2 EK/+ rats (QTRRE cells) with 2,3,5-tris-(glutathion-S-yl) hydroquinone (TGHQ) results in loss of heterozygosity at the Tsc-2 locus in kidney tumors and QTRRE cells. QTRRE cells are carcinogenic in athymic nude mice. Analysis of kidney tumors formed in Tsc-2 EK/+ + rats following 8-months of TGHQ treatment reveals increases in B-Raf, Raf-1, pERK, cyclin D1, p27Kip1, 4EBP1, p-4EBP1(Thr70), p-4EBP1(Ser65), and p-4EBP1(Thr37/46) protein expression. These data establish the involvement of mTOR and MAPK signaling cascades in tuberin null tumors. Similar increases in 4EBP1 and p4EBP1 are observed in renal tumor QTRRE-xenografts in nude mice. Concomitant with increases in expression of these proteins in TGHQ-induced renal tumors, similar changes are observed in QTRRE cells, which also exhibit high ERK, B-Raf and Raf-1 kinase activity; and increased expression of cyclin D1, p27, p-4EBP1 (Thr70), p-4EBP1 (Ser65), and p-4EBP1 (Thr37/46). Manipulation of the Raf/MEK/ERK kinase cascade in QTRRE cells, with kinase inhibitors and siRNA, indicates that Raf-1/MEK/ERK participates in crosstalk with 4EBP1 to regulate translation of cyclin D1.Cyclin D1 and p27 protein levels are increased in the cytoplasm in our RCC models. In normal HK-2 cells, p27 and cyclin D1 are localized to the nucleus. Due to the instability of the cyclin D1-CDK4 complex, p27 interaction is necessary for cyclin D1-CDK4 complex assembly and stabilization in the nucleus. Manipulation of p27 protein levels in QTRRE cells with phosphodiesterase inhibitors, dibutyryl cAMP, and the proteosome inhibitor MG132, all result in a parallel increase in p27 and cyclin D1. Furthermore, p27 siRNA and sorafenib treatment both cause a decrease in p27 and cyclin D1. Further manipulation of cAMP, Rap1B, and B-Raf proteins, revealed that cAMP/PKA/Rap1B/B-Raf activation and B-Raf//ERK MAPK inhibition both modulate p27 expression and compartmental localization in tuberous sclerosis renal cancer. Phosphodiesterase inhibitors play a role in regulating the expression, degradation, and cytoplasmic localization of p27. Therefore, cytoplasmic p27-cyclin D1 mislocalization and stabilization may have an oncogenic role in the cytosol and play a crucial role in tumor formation.

Today, current drug discovery and lead generation efforts focus on high throughput screening of large chemical libraries as the primary source of lead candidates. A lack of investment in novel chemotype development by pharmaceutical companies over the last 15 years coupled with the concurrent merger of screening collections and the availability of generic compound libraries commercially have resulted in many discovery efforts that lack uniqueness and do not offer a strong patent position to operate. The need for better, more diverse, and more drug-like libraries is essential in order to feed high throughput screening efforts with molecules that probe new dimensions of chemical space and allow for the discovery of untapped intellectual property.This dissertation details a complete structure based study to design novel inhibitors of B-Raf and p38a MAP Kinase. A structural evaluation of the important and similar interactions necessary for DFG-out allosteric inhibitors to bind their respective targets was accomplished through the synthesis and evaluation of three known allosteric kinase inhibitors, Gleevec®, Nexavar®, and BIRB-796, and 8 additional DFG-out allosteric inhibitors that were developed directly from fragments of these successful scaffolds. The structural insight that was gained from the evaluation of known DFG-out allosteric inhibitors was then utilized to design novel inhibitors that incorporated two unique scaffolds based on two new [3+2] cycloaddition reactions.A pyrrolo-3,4-dicarboximide scaffold has been developed through the utilization of a novel tandem [3+2] cycloaddition then elimination reaction scheme. This scaffold, which contains three sites for variation, was then rationally incorporated into lead molecules using structure-based methods and in silico feedback for the production of dual DFG-out allosteric kinase inhibitors of p38a and B-Raf kinase. These inhibitors display micromolar to submicromolar enzymatic IC50's for both p38a and B-Raf kinase and low micromolar inhibition of cell growth in 4 separate cancer cell lines.We also explored new chemistry that utilizes a key one pot, [3+2] cycloaddition reaction to obtain highly substituted imidazoles and their application in the design of specific allosteric B-Raf inhibitors. Inhibitors based on this scaffold display subnanomolar potency and a favorable kinase profile.

The data of this thesis show an unexpected role of XIAP and c-IAPs in the turnover of C-RAF protein, thereby modulating the MAPK signaling pathway and cell migration / Die Daten dieser Doktorarbeit zeigen nun eine unerwartete Rolle für XIAP und c-IAPs. Durch ihren Einfluß auf den Proteinumsatz von C-RAF modulieren sie die MAPK-Kaskade und somit die Wanderung von Zellen.

Würzburg, Univ., Diss., 2009. / Zsfassung in dt. Sprache.

Würzburg, Univ., Diss., 2009.

No description available.

The proteins of the RAF family (A-RAF, B-RAF, and C-RAF) are serine/threonine-kinases that play important roles in development, mature cell regulation and cancer. Although it is widely held that their localization on membranes is an important aspect of their function, there are few data addressing this aspect of their mode of action. Here, we report that each member of the RAF family exhibits a specific distribution at the level of cellular membranes, and that C-RAF is the only isoform that directly targets mitochondria. We find that the RAF kinases exhibit intrinsic differences in terms of mitochondrial affinity, and that C-RAF is the only isoform that binds this organelle efficiently. This affinity is conferred by the C-RAF amino-terminal domain, and does not depend on the presence of RAS GTPases on the surface of mitochondria. Furthermore, we analyze the consequences of C-RAF activation on the cellular and molecular level. C-RAF activation on mitochondria dramatically changes their morphology and their subcellular distribution. On the molecular level, we examine the role of C-RAF in the regulation of the pro-apoptotic Bcl-2 family member BAD. This protein exhibits the original mode of regulation by phosphorylation. Although several reports addressed the regulation of BAD by C-RAF, the exact mode of action as well as the consequences of C-RAF activation on BAD are still not completely understood. We show that the inducible activation of C-RAF promotes the rapid phosphorylation of BAD on Serine-112 (Ser-75 in the human protein), through a cascade involving the kinases MEK and RSK. Our findings reveal a new aspect of the regulation of BAD protein and its control by the RAF pathway: we find that C-RAF activation promotes BAD poly-ubiquitylation in a phosphorylation-dependent fashion, and increases the turn-over of this protein through proteasomal degradation. / Die Proteine der RAF-Familie (A-RAF, B-RAF, C-RAF) sind Serin/Threonin-Kinasen, die eine wichtige Rolle in der Entwicklung, in der Zellregulation und in Krebs spielen. Obwohl es weitgehend anerkannt ist, dass die Lokalisation an Membranen ein wichtiger Aspekt ihrer Funktion ist, gibt es nur wenige Daten, die diesen Punkt ihrer Wirkungsweise beschreiben. Wir zeigen hier, dass jedes Mitglied der RAF-Familie eine spezifische Verteilung an zellulären Membranen besitzt, und dass C-RAF die einzige Isoform ist, die direkt an Mitochondrien bindet. Weiterhin zeigen wir, dass RAF-Kinasen intrinsische Unterschiede in ihrer mitochondrialen Affinität aufweisen, wobei C-RAF die einzige Isoform ist, die an dieses Organell effizient bindet. Diese Affinität wird von der amino-terminalen Domäne von C-RAF vermittelt und ist unabhängig vom Vorkommen der RAS-GTPasen auf der Oberfläche von Mitochondrien. Des Weiteren haben wir die Konsequenzen der Aktivierung von C-RAF auf zellulärer als auch auf molekularer Ebene untersucht. C-RAF Aktivierung an Mitochondrien hat drastische Änderungen in deren Morphologie und subzellulärer Verteilung zur Folge. Auf molekularer Ebene haben wir die Rolle von C-RAF in der Regulation des pro-apoptotischen Bcl-2 Familien Proteins BAD untersucht. Dieses Protein wird über Phosphorylierung reguliert. Obwohl eine Vielzahl von Arbeiten die Regulation von BAD durch C-RAF untersuchten, sind die exakte Wirkungsweise wie auch die Konsequenzen der C-RAF Aktivierung im Hinblick auf BAD immer noch unklar. Wir zeigen, dass die induzierbare Aktivierung von C-RAF die rapide Phosphorylierung von BAD an Serin 112 (Serin 75 im humanen Protein) zur Folge hat. Dieser Prozess wird durch eine Kaskade vermittelt, welche die Kinasen MEK und RSK einbezieht. Des Weiteren decken unsere Ergebnisse einen neuen Aspekt der Regulation des BAD Proteins auf und dessen Kontrolle durch den RAF-Signalweg: Wir zeigen, dass die Aktivierung von C-RAF die phosphorylierungs-abhängige Poly-ubiquitylierung von BAD zur Folge hat. Weiterhin beschleunigt die Aktivierung von C-RAF den Umsatz des BAD Proteins durch proteasomalen Abbau.